Matinas BioPharma Holdings, Inc. - MTNB STOCK NEWS

Matinas BioPharma (MTNB) completed enrollment in the ENHANCE-IT Study, evaluating MAT9001 against Vascepa for reducing triglyceride levels. This head-to-head study focuses on the pharmacodynamic effects of MAT9001 and aims to establish its clinical efficacy. Topline data is expected in Q1 2021. The trial includes male and female adults with elevated triglycerides and is conducted at eight U.S. sites. The successful enrollment, achieved in under three months, is seen as a key milestone for the company, promising valuable insights into the omega-3 treatment landscape.

Matinas BioPharma Holdings (MTNB) announced that CEO Jerome D. Jabbour will present at two virtual investor conferences. The first is the LD Micro Virtual Conference on September 2, 2020, at 12:00 p.m. ET, and the second is the HC Wainwright 22nd Annual Global Investment Conference on September 16, 2020, at 12:30 p.m. ET. Both presentations will have live webcasts available on the company’s investor relations page, with replays accessible for 90 days. Matinas is focused on developing MAT9001 for cardiovascular conditions and MAT2203 for invasive fungal infections.

Matinas BioPharma Holdings (MTNB) announced positive results from the Phase 1 portion of the EnACT study for MAT2203, an oral formulation of amphotericin B for cryptococcal meningitis. Published in Antimicrobial Agents and Chemotherapy, the trial demonstrated good safety and tolerability, with reduced toxicity compared to IV amphotericin B. The ongoing Phase 2 trial aims to further evaluate MAT2203's effectiveness in treating HIV-infected patients. MAT2203 has received FDA's QIDP and orphan drug designations, signaling its potential market impact.

Matinas BioPharma Holdings (MTNB) reports second quarter financial results for 2020, continuing progress in key clinical studies while facing challenges from the COVID-19 pandemic. The ENHANCE-IT study of MAT9001 and the EnACT study of MAT2203 have resumed enrollment, with topline data from the former expected in Q1 2021. As of June 30, 2020, the company reported $68 million in cash, up from $27.8 million at the end of 2019, despite a net loss of $5.8 million. Management is optimistic about upcoming catalysts and plans to host a conference call on August 10, 2020.

Matinas BioPharma Holdings (NYSE: MTNB) announced that CEO Jerome D. Jabbour will participate in a fireside chat at the BTIG Virtual Biotech Conference on August 11, 2020, at 9:00 a.m. ET. He will also host investor meetings during the event. Interested investors can contact the conference coordinator for arrangements. A live webcast of the discussion will be available on the Company's website, with a replay accessible for 90 days. Matinas BioPharma focuses on developing MAT9001 for cardiovascular conditions and MAT2203 for serious fungal infections.

Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB) will host a conference call on August 10, 2020, at 4:30 p.m. ET to discuss its second-quarter operational and financial results for the period ending June 30, 2020. To participate, dial (877) 407-5976 for domestic or (412) 902-0031 for international calls. The call will also be accessible via a live audio webcast on the company's website. Matinas focuses on developing MAT9001 for hypertriglyceridemia and MAT2203 for serious fungal infections using its proprietary delivery technology.

Matinas BioPharma (MTNB) has resumed enrollment in its ENHANCE-IT study, comparing MAT9001 to Vascepa, with topline data expected in Q1 2021. Additionally, the company received regulatory approval to restart its EnACT study in Uganda. Expectations are set for rapid patient dosing and progression through clinical stages, indicating potential value creation for shareholders. The ENHANCE-IT study aims to generate clinically meaningful data to support MAT9001's efficacy in treating hypertriglyceridemia while the EnACT study focuses on treating cryptococcal meningitis.

Matinas BioPharma Holdings (MTNB) announced that CEO Jerome D. Jabbour will present a company overview at the Jefferies Virtual Healthcare Conference on June 2, 2020, at 8:00 a.m. ET. He will also host investor meetings during this event. Interested investors can arrange meetings through the conference coordinator. A live webcast will be available on the company's IR calendar page, with a replay accessible for 90 days post-event. Matinas focuses on developing MAT9001 for cardiovascular and metabolic conditions and MAT2203 for serious fungal infections.